Date: May 13, 2022

Administrative Circular: 2022:19

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

- Doses and Schedule:
  A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed. This applies to doses in their primary series, between primary series and first booster dose and between booster doses.

Please remove page numbers: 1-6 dated May 5, 2022
Please add new page numbers: 1-6 dated May 13, 2022

COVID-19 Vaccine SPIKEVAX™ (Moderna)

- Doses and Schedule:
  A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed. This applies to doses in their primary series, between primary series and first booster dose and between booster doses.

Please remove page numbers: 1-5 dated April 26, 2022
Please add new page numbers: 1-5 dated May 13, 2022
COVID-19 Vaccine VAXZEVRITA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

- **Booster Doses:**
  - A footnote has been added to indicate the minimum interval between the primary series and booster dose.
  - A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed.

Please remove page numbers: 1-4 dated April 26, 2022
Please add new page numbers: 1-4 dated May 13, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- **Booster Doses:**
  Footnote A has been revised to indicate that while a second dose of COVID-19 mRNA vaccine is recommended at least 6 months after the first booster dose, clients requesting a shorter interval should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed.

Please remove page numbers: 1-4 dated April 26, 2022
Please add new page numbers: 1-4 dated May 13, 2022

COVID-19 Vaccine Nuvaxovid™ (Novavax)

- **Booster Doses:**
  - A footnote has been added to indicate the minimum interval between the primary series and booster dose.
  - A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed.

Please remove page numbers: 1-3 dated April 26, 2022
Please add new page numbers: 1-3 dated May 13, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPMD
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division